Literature DB >> 15101714

Myeloma of the central nervous system: strong association with unfavorable chromosomal abnormalities and other high-risk disease features.

Athanasios B T Fassas1, Susan Ward, Firas Muwalla, Rudy Van Hemert, Keith Schluterman, Sami Harik, Guido Tricot.   

Abstract

Involvement of the central nervous system (CNS) by multiple myeloma, defined by the detection of malignant plasma cells in the cerebrospinal fluid in the presence of suggestive symptoms, is considered extremely rare. We present the characteristics of 25 such patients (18 previously reported) intended to receive high-dose treatment at the University of Arkansas over the last 12 years; an extensive review of the published literature since 1968, including 71 patients, is also presented. In both patient groups, high tumor burden was overwhelmingly present while circulating plasma cells were detected in a significant proportion of cases. We also observed a strong association of CNS involvement with unfavorable cytogenetic abnormalities (especially translocations and deletion of the chromosome 13), plasmablastic morphology and additional extramedullary myeloma manifestations. The presence of these features should alert clinicians to the possibility of CNS involvement. The prognosis of such patients is poor despite aggressive systemic and local treatment and reflects the underlying disease biology. Application of allogeneic transplantation and administration of prophylactic CNS treatment are also discussed. Further elucidation of the factors predisposing patients with high-risk disease features to CNS myeloma involvement is needed.

Entities:  

Mesh:

Year:  2004        PMID: 15101714     DOI: 10.1080/10428190310001597964

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  19 in total

1.  Multiple myeloma presenting with complex cranial nerve palsies.

Authors:  Andrea Wong; Noorainun Md Yusof; Sing-Huang Tan; Wee J Chng
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

Review 2.  How We Manage Patients with Plasmacytomas.

Authors:  Despina Fotiou; Meletios A Dimopoulos; Efstathios Kastritis
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

3.  Testicular Plasmacytoma Masking as Epididymo-orchitis in a Known Multiple Myeloma Patient.

Authors:  Urwat Til Vusqa; Palash Asawa; Salman Fazal; Yazan Samhouri
Journal:  Cancer Diagn Progn       Date:  2022-09-03

4.  Clinical Characteristics and Prognosis of Multiple Myeloma With Myelomatous Pleural Effusion: A Retrospective Single-Center Study.

Authors:  Liang Gao; Junhui Xu; Weiwei Xie; Bingjie Wang; Xinan Cen; Mangju Wang
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

5.  Fatal cerebral hemorrhage in a patient with CD19-positive IgM-producing aggressive plasma cell myeloma, hyperviscosity syndrome and cryoglobulinemia.

Authors:  Adnan Alatoom; Rania Elsabrouty; Jason Willis; Christie Boils; Ravindra Sarode; Ibrahim Hashim; Huan-You Wang
Journal:  Int J Clin Exp Pathol       Date:  2009-02-09

6.  Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.

Authors:  Artur Jurczyszyn; Norbert Grzasko; Alessandro Gozzetti; Jacek Czepiel; Alfonso Cerase; Vania Hungria; Edvan Crusoe; Ana Luiza Miranda Silva Dias; Ravi Vij; Mark A Fiala; Jo Caers; Leo Rasche; Ajay K Nooka; Sagar Lonial; David H Vesole; Sandhya Philip; Shane Gangatharan; Agnieszka Druzd-Sitek; Jan Walewski; Alessandro Corso; Federica Cocito; Marie-Christine M Vekemans; Erden Atilla; Meral Beksac; Xavier Leleu; Julio Davila; Ashraf Badros; Ekta Aneja; Niels Abildgaard; Efstathios Kastritis; Dorotea Fantl; Natalia Schutz; Tomas Pika; Aleksandra Butrym; Magdalena Olszewska-Szopa; Lidia Usnarska-Zubkiewicz; Saad Z Usmani; Hareth Nahi; Chor S Chim; Chaim Shustik; Krzysztof Madry; Suzanne Lentzsch; Alina Swiderska; Grzegorz Helbig; Renata Guzicka-Kazimierczak; Nikoletta Lendvai; Anders Waage; Kristian T Andersen; Hirokazu Murakami; Sonja Zweegman; Jorge J Castillo
Journal:  Am J Hematol       Date:  2016-04-24       Impact factor: 10.047

Review 7.  Risk Stratification in Multiple Myeloma.

Authors:  Melissa Gaik-Ming Ooi; Sanjay de Mel; Wee Joo Chng
Journal:  Curr Hematol Malig Rep       Date:  2016-04       Impact factor: 3.952

8.  Case study of intracerebral plasmacytoma as an initial presentation of multiple myeloma.

Authors:  Aurelia Wavre; Audrey S Baur; Michael Betz; Dominique Mühlematter; Martine Jotterand; Khalil Zaman; Nicolas Ketterer
Journal:  Neuro Oncol       Date:  2007-05-23       Impact factor: 12.300

9.  A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma.

Authors:  C S Chim; A K W Lie; E Y T Chan; Y Y Leung; S C W Cheung; S Y T Chan; Raymond Liang; Y L Kwong
Journal:  Ann Hematol       Date:  2010-04-29       Impact factor: 3.673

10.  Extramedullary plasmacytoma in the presence of multiple myeloma: clinical correlates and prognostic relevance.

Authors:  Hai-Fei Chen; Tian-Qin Wu; Zheng-Yang Li; Hong-Shi Shen; Jie-Qing Tang; Wei-Jun Fu; Zhen-Gang Yuan; Jian Hou
Journal:  Onco Targets Ther       Date:  2012-11-07       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.